FDA OKs Once-Monthly Subcutaneous Amivantamab Dose in EGFR+ NSCLC
Pause on Lorigerlimab Trial: The FDA has placed a partial clinical hold on the Lorigerlimab trial in gynecologic cancers due to serious safety events. This new development underscores the potential risks inherent in exploring new cancer treatments.
Mitigating Melanoma Treatment Side Effects: Progress has been made in managing immune-checkpoint inhibitor toxicities in Melanoma treatments, signalling potential improvements in the efficacy and tolerance of such therapies.
FDA Endorses New Treatment: The FDA has granted fast track designation to SRN-101, immuno-gene therapy for the treatment of recurrent high-grade glioma, highlighting the urgency in addressing this form of devastating disease.
Progress in Multiple Myeloma Treatment: Early activity has been observed in the use of a novel small molecule, KTX-1001, in pretreated Multiple Myeloma, opening new potential pathways in the treatment of this cancer type.
New Data on Proton Therapy: 2025 data reveal promising outcomes in quality of life with the use of proton therapy in oropharyngeal cancer, including immune preservation and reduction of long-term adverse effects, underscoring the advances made in the field of oncology.
